HERIZON: Phase 2 part of the IMU-131 HER2/neu vaccine plus chemotherapy study randomized in patients with HER2/NEU overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction

Category Primary study
JournalANNALS OF ONCOLOGY
Year 2021
This article has no abstract
Epistemonikos ID: 1e40b30f273eefd1ac6ec56c27c5c34d8fbd9817
First added on: Feb 12, 2025